Literature DB >> 17335929

Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s.

Peter Ferenci1, Stefan Ferenci, Christian Datz, Ingo Rezman, Wilhelm Oberaigner, Reinhild Strauss.   

Abstract

BACKGROUND/AIMS: Between 1964 and 1987 several epidemic outbreaks of hepatitis C virus infection linked to plasma donation occurred at plasmapheresis centres in Austria. Data collected by a Foundation to help the victims enabled us to study the natural history of chronic hepatitis C in this cohort.
METHODS: Medical records and charts of donors accepted by the Foundation were analyzed.
RESULTS: Four hundred and eighty-five subjects (439 males; mean age at infection: 22 years) were included. Mean follow-up was 31 years. Thirty-four percent of plasma donors had advanced liver disease; alcohol abuse and diabetes were related to progression. Twenty-one patients developed hepatocellular carcinoma; 36 underwent liver transplantation. Six donors cleared the virus spontaneously. Forty died, with death directly related to liver disease in 25 donors. Overall and transplant-free 35-year cumulative survival rates were 84% and 74%, respectively. Three hundred and nineteen patients received and 291 completed antiviral treatment. All 56 who achieved a sustained virologic response are alive and well; 14 non-responders died and nine underwent liver transplantation.
CONCLUSIONS: Thirty-one years after virus infection, advanced liver disease has developed in a third of patients, with an overall mortality of 7%. These data underline the progressive nature of chronic hepatitis C infection and the need to identify and treat infected subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335929     DOI: 10.1016/j.jhep.2007.01.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

Review 1.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 2.  The history of the "natural history" of hepatitis C (1968-2009).

Authors:  Leonard B Seeff
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

3.  Long-Term Follow-Up of a Portuguese Single-Centre Cohort of Persons with Haemophilia and Hepatitis C Virus Infection.

Authors:  Tiago Pereira Guedes; Mónica Garrido; Ricardo Kuttner Magalhães; Teresa Moreira; Marta Rocha; Luís Maia; José Manuel Ferreira; Sara Morais; Isabel Pedroto
Journal:  GE Port J Gastroenterol       Date:  2020-09-29

4.  Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.

Authors:  Yasmine S El Abd; Ashraf A Tabll; Noha G Bader El Din; Alaa El-Dien S Hosny; Rehab I Moustafa; Reem El-Shenawy; Khaled Atef; Mostafa K El-Awady
Journal:  Virol J       Date:  2011-08-05       Impact factor: 4.099

5.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.

Authors:  Mark Hull; Stephen Shafran; Alex Wong; Alice Tseng; Pierre Giguère; Lisa Barrett; Shariq Haider; Brian Conway; Marina Klein; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-07-04       Impact factor: 2.471

6.  Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats.

Authors:  Mostafa K El-Awady; Ashraf A Tabll; Yasmine S El-Abd; Hassan Yousif; Mohsen Hegab; Mohamed Reda; Reem El Shenawy; Rehab I Moustafa; Nabila Degheidy; Noha G Bader El Din
Journal:  Virol J       Date:  2009-05-27       Impact factor: 4.099

7.  Impact of IL12B gene rs 3212227 polymorphism on fibrosis, liver inflammation, and response to treatment in genotype 4 Egyptian hepatitis C patients.

Authors:  Samar Samir Youssef; Asmaa Mostafa; Amr Saad; Moataza Hassan Omran; Taher El Zanaty; Sameh Mohamed Seif
Journal:  Dis Markers       Date:  2013-10-01       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.